Opinion

Video

More Is Needed to Connect Clinicians, Patients to Clinical Trials

Author(s):

More facilitation is needed to ensure that clinicians can connect patients with breast cancer to clinical trials they may be eligible for.

More needs to be done to facilitate a connection between oncology nurse navigators and clinical resources to improve enrollment and diversify the patient population involved in research, explained Sue Friedman.

In an interview with CURE®, Friedman, who is the executive director of FORCE (Facing Hereditary Cancer Empowered) discussed a needs assessment conducted by FORCE and supported by the Centers of Disease Control and Prevention (CDC), which highlighted barriers for referrals to supportive care services and clinical trials for young patients with breast cancer.

READ MORE: Knowledge is Power’: Advocating for More Representation in Cancer-Related Clinical Trials

Now, Friedman explained, FORCE will work to facilitate that collaboration to improve clinical trial enrollment and break down barriers to supportive care, such as fertility preservation.

Transcript

Well, there were several big takeaways from our needs assessment, and this poster was really just one component of it, but one was that there was more that we could do as an organization to facilitate connecting oncology nurse navigators with resources around clinical research studies to help encourage them to let patients know more about clinical research studies in order to improve enrollment and diverse involvement in clinical research.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.